Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Lorus Therapeutics Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Dan who wrote (96)	3/18/1998 1:13:00 PM
From: Gravitar	Read Replies (1) \| Respond to of 279

Imutec Pharma Receives Patent Approval for Virulizin(r) PR Newswire - March 18, 1998 12:54 TORONTO, March 18 /CNW-PRN/ - Imutec Pharma Inc. announced today that it has received a Notice of Allowance from the Canadian Intellectual Property Office (CIPO) for the Company's lead product, Virulizin(R). The Notice of Allowance encompasses 39 claims and covers both the composition and use of Virulizin(R) in the treatment of cancer. The patent approval, which was based on Application No. 2,171,281, was submitted to the CIPO on September 9, 1994. ''The allowance of this patent by the Canadian Patent Office is significant not only because of the protection it provides but because the CIPO is considered one of the most stringent patent agencies in the world,'' said Philippe G. Lacaille, President and Chief Executive Officer. ''Strong intellectual property is a key component of our business strategy. This patent will certainly help us in our discussions with our potential partners regarding the licensing of Virulizin(R).'' Since September 1993, Imutec Pharma has filed several international patent applications for Virulizin(R) covering the composition, method of preparation, and use of the product in the treatment of cancer and other diseases. The allowance of this patent by the Canadian Patent Office is the first approval obtained by Imutec Pharma and is expected to be followed by other approvals later this year. Two families of U.S., European and other Patent Applications for Virulizin(R) have also been filed, and are currently pending review by examiners in several National Patent Offices. Imutec Pharma Inc. is a pharmaceutical company engaged in the development and commercialization of innovative products for the treatment of cancer and certain viral diseases. Through an active acquisition and in-licensing program, Imutec Pharma's goal is to build and clinically develop a portfolio of innovative drugs targeted at life-threatening diseases. Thereafter, Imutec Pharma intends to undertake late stage clinical development and marketing in cooperation with strategic pharmaceutical partners. Founded in 1986, Imutec Pharma Inc. is a public company listed on the Toronto Stock Exchange and the Montreal Stock Exchange under the symbol IMT and on the NASDAQ exchange under the symbol IMUTF. Except for historical information, this press release contains forward-looking statements which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties which may cause actual results to differ materially from those statements. Those risks and uncertainties include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time-to-time in the Company's ongoing quarterly filings, annual reports and 20-F filings. Imutec Pharma's press releases are available through the Company's Internet site: imutec.com